Výsledky vyhledávání - "J.-P. Courreges"

Akademický článek

Lack of phosphatidylinositol 3-kinase VPS34 in regulatory T cells leads to a fatal lymphoproliferative disorder without affecting their development

Autor: Christina J. F. Courreges, Elizabeth C. M. Davenport, Benoit Bilanges, Elena Rebollo-Gomez, Jens Hukelmann, Priya Schoenfelder, James R. Edgar, David Sansom, Cheryl L. Scudamore, Rahul Roychoudhuri, Oliver A. Garden, Bart Vanhaesebroeck, Klaus Okkenhaug

Publikováno v: Frontiers in Immunology, Vol 15 (2024)

Regulatory T (Treg) cells are essential for the maintenance of immunological tolerance, yet the molecular components required for their maintenance and effector functions remain incompletely defined. Inactivation of VPS34 in Treg cells led to an earl

Externí odkaz: https://doaj.org/article/76c0dafb2bb54d09976bae31a2ce382f

Zobrazit plný text záznamu

The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial

Autor: Bruce W. Bode, Louis B. Chaykin, Sultan Linjawi, Yehuda Handelsman, Lucine Lehmann, J.-P. Courreges, Abhishek Mishra, Richard W Simpson

Publikováno v: Diabetes Therapy

Introduction The progressive nature of type 2 diabetes necessitates treatment intensification. This often involves intensification with oral antidiabetic drugs (OADs) initially, followed by other agents, such as glucagon-like peptide-1 receptor agoni

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01e8de67df9ad79406bac96f4f8aeb2c
https://pubmed.ncbi.nlm.nih.gov/27943107

Zobrazit plný text záznamu

Insulin Degludec/Insulin Aspart Administered Once Daily at Any Meal, With Insulin Aspart at Other Meals Versus a Standard Basal-Bolus Regimen in Patients With Type 1 Diabetes

Autor: Patrik Dykiel, Henriette Mersebach, Bruce W. Bode, Edward Franek, Melanie J. Davies, Irl B. Hirsch, J.-P. Courreges, Kjeld Hermansen, Allen B King

Publikováno v: Diabetes Care. 35:2174-2181

OBJECTIVE To evaluate efficacy and tolerability of a co-formulation of insulin degludec and insulin aspart (IDegAsp) with insulin aspart (IAsp) at other meals compared with basal-bolus therapy using insulin detemir (IDet) and IAsp. RESEARCH DESIGN AN

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f848758b7e0fd2262884ed027c5b6541
https://doi.org/10.2337/dc11-2503

Zobrazit plný text záznamu

Étude DUAL III : efficacité et tolérance de l’association degludec/liraglutide (IDegLira) chez les patients diabétiques de type 2 naïfs d’insuline et insuffisamment contrôlés par agonistes du récepteur du GLP-1

Autor: D. Gouet, Y. Handelsman, Richard W Simpson, S. Linjawi, Lucine Lehmann, A. Mishra, L. Chaykin, A. Bouzidi, J.-P. Courreges

Publikováno v: Annales d'Endocrinologie. 77:324-325

Objectif Etudier l’efficacite et la tolerance de l’association a ratio fixe de l’insuline degludec (IDeg) et du liraglutide (Lira) IDegLira sur le controle glycemique chez les patients diabetiques de type 2 (DT2) insuffisamment controles avec u

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0a24f3a7ac312811adf3c06150f69b54
https://doi.org/10.1016/j.ando.2016.07.230

Zobrazit plný text záznamu

Résultats intermédiaires de l’étude I RESIST : sécurité d’un traitement par pompe à insuline S/C ambulatoire chez des diabétiques de type 2 (DT2) insulino-résistants

Autor: S. Clavel, F. Travert, P. Serusclat, E. Ghanassia, J.-P. Courreges, D. Huet

Publikováno v: Annales d'Endocrinologie. 77:503

Introduction Quelle securite peut-on attendre d’un traitement par pompe a insuline ambulatoire (PIA) chez des patients DT2 souvent âges et fragiles ? Patients et methodes Nous analysons les resultats intermediaires (n = 70 a T6, n = 55, a T12) de

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cdb00052f69638b014398b18146f695a
https://doi.org/10.1016/j.ando.2016.07.761

Zobrazit plný text záznamu

Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes

Autor: I. Buganova, Sten Madsbad, R. Verhoeven, Milan Zdravkovic, T. Le-Thi, Thure Krarup, Tina Vilsbøll, J.-P. Courreges, Ole Schmitz

Publikováno v: Diabetic Medicine
Courrèges, J-P, Vilsbøll, T, Zdravkovic, M, Le-Thi, T, Krarup, T, Schmitz, O, Verhoeven, R, Bugáñová, I & Madsbad, S 2008, ' Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes ', Diabetic Medicine, vol. 25, no. 9, pp. 1129-31 . https://doi.org/10.1111/j.1464-5491.2008.02484.x

Liraglutide is a once-daily, human glucagon-like peptide-1 (GLP-1) analogue. Clinical studies have demonstrated blood glucose and weight-reducing effects, improvements in pancreatic B-cell function and a low risk of hypoglycaemic events with liraglut

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::107fbf9107f6418b9d3045bddc4c76ea
https://pubmed.ncbi.nlm.nih.gov/19183322

Zobrazit plný text záznamu

Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes

Autor: Robert Verhoeven, Tina Vilsbøll, Tu Le-Thi, Ole Schmitz, Sten Madsbad, Ingrid Bugánová, Thure Krarup, Milan Zdravkovic, J.-P. Courreges

Publikováno v: Diabetes care. 30(6)

Liraglutide is a long-acting human glucagon-like peptide-1 (GLP-1) analog (1–4), and the current study was undertaken to evaluate efficacy and safety after 14 weeks' treatment with liraglutide in patients with type 2 diabetes. Main inclusion criter

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::baf6fb9b93d612459c9c4cf458291e6a
https://pubmed.ncbi.nlm.nih.gov/17372153

Zobrazit plný text záznamu

ÉTUDE I RESIST : instauration d’un traitement par pompe insuline ambulatoire chez des diabétiques insulino résistants, en échec de bon contrôle glycémique

Autor: J.-P. Courreges, D. Gouet, D. Huet, P. Serusclat, F. Travert, S. Clavel

Publikováno v: Annales d'Endocrinologie. 76:374

Introduction L’etude I RESIST analyse le benefice de l’instauration d’une pompe a insuline ambulatoire sous-cutanee (PAI) chez des DT2 en echec prolonge d’insulinotherapie majeure et multiple. Patients et methodologie I RESIST est une etude n

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::242bdbd7ec4da7c4869e8a290e85cb8f
https://doi.org/10.1016/j.ando.2015.07.230

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání